Skip to main content Skip to navigation

Dr Louise Hiller

Job Title
Associate Professor (Research Focussed)
Department
WMS - Warwick Clinical Trials Unit
Phone
02476150179
Research Interests

I work predominately on randomised Phase II and III Breast Cancer Clinical Trials, analysing the clinical data from these as well as their Proteomics and Genomics sub-studies. I have previously researched into outcome measures in Obstetrics and Gynaecology, writing a PhD on the Evaluation of the Statistical Validation of Questionnaires for use as Outcome Measures in Clinical Trials.

  • Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi et al (Select to open full list), 2024.

    All authors for Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study

    Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi, Raveendran, Sinthuri, Hero, Emily, Evans, Harriet, Osman, Rania, Fatima, Khunsha, Hughes, Rhian W., McIntosh, Stuart A., Moran, Gordon W., Ortiz?Fernandez?Sordo, Jacobo, Rajpoot, Nasir M., Storey, Ben, Ahmed, Imtiaz, Dunn, Janet A., Hiller, Louise, Snead, David R. J.

    Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study. Histopathology
  • Quenby, Siobhan, Booth, Katie, Hiller, Louise, Coomarasamy, Arri, de Jong, Paulien G., Hamulyák, Eva N., Scheres, Luuk J., van Haaps, Thijs F., Ewington, Lauren J., Tewary, Shreeya, Goddijn, Mariëtte, Middeldorp, Saskia, 2023. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2) : an international open-label, randomised controlled trial. Lancet, 402 (10395), pp. 54-61
  • 'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R. et al (Select to open full list), 2022.

    All authors for 'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients

    'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R., 'Valero, V., 'Edge, S. B., 'Abraham, J. E., 'Bartlett, J. M. S., 'Caldas, C., 'Dunn, Janet A., 'Earl, H. M., 'Hayward, L., 'Hiller, Louise, 'Provenzano, E., 'Sammut, S. J., 'Thomas, J. S., 'Cameron, D., 'Graham, A., 'Hall, P., 'Mackintosh, L., 'Fan, F., 'Godwin, A. K., 'Schwensen, K., 'Sharma, P., 'DeMichele, A. M., 'Cole, K., 'Pusztai, L., 'Kim, M., 'van?t Veer, L. J., 'Esserman, L. J., 'Symmans, W. F.

    'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients. Lancet Oncology, 23 (1), pp. 149-160
  • 'Sudin, Ellhia, 'Searjeant, Mitchell, 'Partridge, George, 'Phillips, Peter W., 'Hiller, Louise, 'Snead, David R. J., 'Ellis, Ian O., 'Chen, Yan, 2022. 'Digital pathology : the effect of experience on visual search behavior. Journal of Medical Imaging, 9 (03)
  • Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M. et al (Select to open full list), 2022.

    All authors for Multi-omic machine learning predictor of breast cancer therapy response

    Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M., Caldas, Carlos

    Multi-omic machine learning predictor of breast cancer therapy response. Nature, 601, pp. 623-629
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen, Hall, Peter, Mansi, Janine, Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David, Cameron , David, Wardley, Andrew, 2021. Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33 (1), pp. 15-19
  • Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020.

    All authors for Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT

    Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter, Shinkins, Bethany, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M., Cameron, David A., Dunn, Janet A.

    Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
  • Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019.

    All authors for 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

    Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler?Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A.

    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
  • Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie et al (Select to open full list), 2019.

    All authors for Genome-wide association study of germline variants and breast cancer-specific mortality

    Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie, Blomqvist, Carl, Boeckx, Bram, Bojesen, Stig E., Bonanni, Bernardo, Børresen-Dale, Anne-Lise, Brauch, Hiltrud, Brenner, Hermann, Brentnall, Adam, Brinton, Louise, Broberg, Per, Brock, Ian W., Brucker, Sara Y., Burwinkel, Barbara, Caldas, Carlos, Caldés, Trinidad, Campa, Daniele, Canzian, Federico, Carracedo, Angel, Carter, Brian D., Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Cheng, Ting-Yuan David, Chin, Suet-Feung, Clarke, Christine L., Cordina-Duverger, Emilie, Couch, Fergus J., Cox, David G., Cox, Angela, Cross, Simon S., Czene, Kamila, Daly, Mary B., Devilee, Peter, Dunn, Janet A., Dunning, Alison M., Durcan, Lorraine, Dwek, Miriam, Earl, Helena M., Ekici, Arif B., Eliassen, A. Heather, Ellberg, Carolina, Engel, Christoph, Eriksson, Mikael, Evans, D. Gareth, Figueroa, Jonine, Flesch-Janys, Dieter, Flyger, Henrik, Gabrielson, Marike, Gago-Dominguez, Manuela, Galle, Eva, Gapstur, Susan M., García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., George, Angela, Georgoulias, Vassilios, Giles, Graham G., Glendon, Gord, Goldgar, David E., González-Neira, Anna, Alnæs, Grethe I. Grenaker, Grip, Mervi, Guénel, Pascal, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Hamann, Ute, Hankinson, Susan, Harkness, Elaine F., Harrington, Patricia A., Hart, Steven N., Hartikainen, Jaana M., Hein, Alexander, Hillemanns, Peter, Hiller, Louise, Holleczek, Bernd, Hollestelle, Antoinette, Hooning, Maartje J., Hoover, Robert N., Hopper, John L., Howell, Anthony, Huang, Guanmengqian, Humphreys, Keith, Hunter, David J., Janni, Wolfgang, John, Esther M., Jones, Michael E., Jukkola-Vuorinen, Arja, Jung, Audrey, Kaaks, Rudolf, Kabisch, Maria, Kaczmarek, Katarzyna, Kerin, Michael J., Khan, Sofia, Khusnutdinova, Elza, Kiiski, Johanna I., Kitahara, Cari M., Knight, Julia A., Ko, Yon-Dschun, Koppert, Linetta B., Kosma, Veli-Matti, Kraft, Peter, Kristensen, Vessela N., Krüger, Ute, Kühl, Tabea, Lambrechts, Diether, Le Marchand, Loic, Lee, Eunjung, Lejbkowicz, Flavio, Li, Lian, Lindblom, Annika, Lindström, Sara, Linet, Martha, Lissowska, Jolanta, Lo, Wing-Yee, Loibl, Sibylle, Lubinski, Jan, Lux, Michael P., MacInnis, Robert J., Maierthaler, Melanie, Maishman, Tom, Makalic, Enes, Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush, Margolin, Sara, Martinez, Maria Elena, Mavroudis, Dimitrios, McLean, Catriona, Meindl, Alfons, Middha, Pooja, Miller, Nicola, Milne, Roger L., Moreno, Fernando, Mulligan, Anna Marie, Mulot, Claire, Nassir, Rami, Neuhausen, Susan L., Newman, William T., Nielsen, Sune F., Nordestgaard, Børge G., Norman, Aaron, Olsson, Håkan, Orr, Nick, Pankratz, V. Shane, Park-Simon, Tjoung-Won, Perez, Jose I. A., Pérez-Barrios, Clara, Peterlongo, Paolo, Petridis, Christos, Pinchev, Mila, Prajzendanc, Karoliona, Prentice, Ross, Presneau, Nadege, Prokofieva, Darya, Pylkäs, Katri, Rack, Brigitte, Radice, Paolo, Ramachandran, Dhanya, Rennert, Gadi, Rennert, Hedy S., Rhenius, Valerie, Romero, Atocha, Roylance, Rebecca, Saloustros, Emmanouil, Sawyer, Elinor J., Schmidt, Daniel F., Schmutzler, Rita K., Schneeweiss, Andreas, Schoemaker, Minouk J., Schumacher, Fredrick, Schwentner, Lukas, Scott, Rodney J., Scott, Christopher, Seynaeve, Caroline, Shah, Mitul, Simard, Jacques, Smeets, Ann, Sohn, Christof, Southey, Melissa C., Swerdlow, Anthony J., Talhouk, Aline, Tamimi, Rulla M., Tapper, William J., Teixeira, Manuel R., Tengström, Maria, Terry, Mary Beth, Thöne, Kathrin, Tollenaar, Rob A. E. M., Tomlinson, Ian, Torres, Diana, Truong, Thérèse, Turman, Constance, Turnbull, Clare, Ulmer, Hans-Ulrich, Untch, Michael, Vachon, Celine, van Asperen, Christi J., van den Ouweland, Ans M. W., van Veen, Elke M., Wendt, Camilla, Whittemore, Alice S., Willett, Walter, Winqvist, Robert, Wolk, Alicja, Yang, Xiaohong R., Zhang, Yan, Easton, Douglas F., Fasching, Peter A., Nevanlinna, Heli, Eccles, Diana M., Pharoah, Paul D. P., Schmidt, Marjanka K.

    Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120 (6), pp. 647-657
  • Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
  • Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien et al (Select to open full list), 2017.

    All authors for Body mass index and breast cancer survival : a Mendelian randomization analysis

    Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien, Burwinkel, Barbara, Caldas, Carlos, Campa, Daniele, Canzian, Federico, Chang-Claude, Jenny, Chanock, Stephen J., Chin, Suet-Feung, Couch, Fergus J., Cox, Angela, Cross, Simon S., Cybulski, Cezary, Czene, Kamila, Darabi, Hatef, Devilee, Peter, Diver, W Ryan, Dunning, Alison M., Earl, Helena M., Eccles, Diana M., Ekici, Arif B., Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A., Figueroa, Jonine, Flesch-Janys, Dieter, Flyger, Henrik, Gapstur, Susan M., Gaudet, Mia M., Giles, Graham G., Glendon, Gord, Grip, Mervi, Gronwald, Jacek, Haeberle, Lothar, Haiman, Christopher A., Hall, Per, Hamann, Ute, Hankinson, Susan, Hartikainen, Jaana M., Hein, Alexander, Hiller, Louise, Hogervorst, Frans B., Holleczek, Bernd, Hooning, Maartje J., Hoover, Robert N., Humphreys, Keith, Hunter, David J., Hüsing, Anika, Jakubowska, Anna, Jukkola-Vuorinen, Arja, Kaaks, Rudolf, Kabisch, Maria, Kataja, Vesa, Knight, Julia A., Koppert, Linetta B., Kosma, Veli-Matti, Kristensen, Vessela N., Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Lindblom, Annika, Lindström, Sara, Lissowska, Jolanta, Lubinski, Jan, Machiela, Mitchell J., Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Marme, Federik, Martens, John WM, McLean, Catriona, Menéndez, Primitiva, Milne, Roger L, Marie Mulligan, Anna, Muranen, Taru A., Nevanlinna, Heli, Neven, Patrick, Nielsen, Sune F., Nordestgaard, Børge G., Olson, Janet E., Perez, Jose I. A., Peterlongo, Paolo, Phillips, Kelly-Anne, Poole, Christopher J., Pylkäs, Katri, Radice, Paolo, Rahman, Nazneen, Rüdiger, Thomas, Rudolph, Anja, Sawyer, Elinor J., Schumacher, Fredrick, Seibold, Petra, Seynaeve, Caroline, Shah, Mitul, Smeets, Ann, Southey, Melissa C., Tollenaar, Rob A. E. M., Tomlinson, Ian, Tsimiklis, Helen, Ulmer, Hans-Ulrich, Vachon, Celine, Ouweland, Ans M. W. van den, Van't Veer, Laura J., Wildiers, Hans, Willett, Walter, Winqvist, Robert, Zamora, M Pilar, Chenevix-Trench, Georgia, Dörk, Thilo, Easton, Douglas F., García-Closas, Montserrat, Kraft, Peter, Hopper, John L., Zheng, Wei, Schmidt, Marjanka K., Pharoah, Paul D. P.

    Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6), pp. 1814-1822
  • Earl, H. M., Hiller, Louise, Dunn, Janet A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial. Annals of Oncology, 28 (8), pp. 1817-1824
  • Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, Janet A., Hiller, Louise, Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C., 2017. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer : secondary analysis of the ARTemis trial. Annals of Oncology, 28 (8), pp. 1832-1835
  • Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence et al (Select to open full list), 2017.

    All authors for Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

    Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence, Earl, Helena Margaret

    Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), pp. 1069-1077
  • Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos et al (Select to open full list), 2017.

    All authors for Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial

    Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos, Provenzano, Elena, Abraham, Jean E., Canney, Peter, Crown, John P., Kennedy, M John, Coleman, Robert, Leonard, Robert C., Carmichael, James A., Wardley, Andrew M., Poole, Christopher J.

    Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18 (6), pp. 755-769
  • Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
  • Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
  • Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos, 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1)
  • Thamm, Douglas, Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
  • Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J. et al (Select to open full list), 2016.

    All authors for A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J., Gillson, C., Al Olama, A. A., Amouyel, P., Arriola, L., Arveiler, D., Aviles-Olmos, I., Balkau, B., Barricarte, A., Barroso, I., Garcia, S. B., Bis, J. C., Blankenberg, S., Boehnke, M., Boeing, H., Boerwinkle, E., Borecki, I. B., Bork-Jensen, J., Bowden, S., Caldas, C., Caslake, M., Cupples, L. A., Cruchaga, C., Czajkowski, J., den Hoed, M., Dunn, Janet A., Earl, H. M., Ehret, G. B., Ferrannini, E., Ferrieres, J., Foltynie, T., Ford, I., Forouhi, N. G., Gianfagna, F., Gonzalez, C., Grioni, S., Hiller, Louise, Jansson, J.-H., Jorgensen, M. E., Jukema, J. W., Kaaks, R., Kee, F., Kerrison, N. D., Key, T. J., Kontto, J., Kote-Jarai, Z., Kraja, A. T., Kuulasmaa, K., Kuusisto, J., Linneberg, A., Liu, C., Marenne, G., Mohlke, K. L., Morris, A. P., Muir, K., Muller-Nurasyid, M., Munroe, P. B., Navarro, C., Nielsen, S. F., Nilsson, P. M., Nordestgaard, B. G., Packard, C. J., Palli, D., Panico, S., Peloso, G. M., Perola, M., Peters, A., Poole, C. J., Quiros, J. R., Rolandsson, O., Sacerdote, C., Salomaa, V., Sanchez, M.-J., Sattar, N., Sharp, S. J., Sims, R., Slimani, N., Smith, J. A., Thompson, D. J., Trompet, S., Tumino, R., van der A, D. L., van der Schouw, Y. T., Virtamo, J., Walker, M., Walter, K., Abraham, J. E., Amundadottir, L. T., Aponte, J. L., Butterworth, A. S., Dupuis, J., Easton, D. F., Eeles, R. A., Erdmann, J., Franks, P. W., Frayling, T. M., Hansen, T., Howson, J. M. M., Jorgensen, T., Kooner, J., Laakso, M., Langenberg, C., McCarthy, M. I., Pankow, J. S., Pedersen, O., Riboli, E., Rotter, J. I., Saleheen, D., Samani, N. J., Schunkert, H., Vollenweider, P., ORahilly, S., Deloukas, P., Danesh, J., Goodarzi, M. O., Kathiresan, S., Meigs, J. B., Ehm, M. G., Wareham, N. J., Waterworth, D. M.

    A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8 (341)
  • Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos, Earl, Helena M., 2015. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1)
  • Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D. et al (Select to open full list), 2015.

    All authors for Identification of Novel Genetic Markers of Breast Cancer Survival

    Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D., Weltens, C., Leunen, K., Bojesen, S. E., Nordestgaard, B. G., Nielsen, S. F., Flyger, H., Chang-Claude, J., Rudolph, A., Seibold, P., Flesch-Janys, D., Blomqvist, C., Aittomaki, K., Fagerholm, R., Muranen, T. A., Couch, F. J., Olson, J. E., Vachon, C., Andrulis, I. L., Knight, J. A., Glendon, G., Mulligan, A. M., Broeks, A., Hogervorst, F. B., Haiman, C. A., Henderson, B. E., Schumacher, F., Le Marchand, L., Hopper, J. L., Tsimiklis, H., Apicella, C., Southey, M. C., Cox, A., Cross, S. S., Reed, M. W. R., Giles, G. G., Milne, R. L., McLean, C., Winqvist, R., Pylkas, K., Jukkola-Vuorinen, A., Grip, M., Hooning, M. J., Hollestelle, A., Martens, J. W. M., van den Ouweland, A. M. W., Marme, F., Schneeweiss, A., Yang, R., Burwinkel, B., Figueroa, J., Chanock, S. J., Lissowska, J., Sawyer, E. J., Tomlinson, I., Kerin, M. J., Miller, N., Brenner, H., Dieffenbach, A. K., Arndt, V., Holleczek, B., Mannermaa, A., Kataja, V., Kosma, V.-M., Hartikainen, J. M., Li, J., Brand, J. S., Humphreys, K., Devilee, P., Tollenaar, R. A. E. M., Seynaeve, C., Radice, P., Peterlongo, P., Bonanni, B., Mariani, P., Fasching, P. A., Beckmann, M. W., Hein, A., Ekici, A. B., Chenevix-Trench, G., Balleine, R., Phillips, K.-A., Benitez, J., Zamora, M. P., Arias Perez, J. I., Menendez, P., Jakubowska, A., Lubinski, J., Jaworska-Bieniek, K., Durda, K., Hamann, U., Kabisch, M., Ulmer, H. U., Rudiger, T., Margolin, S., Kristensen, V., Nord, S., Evans, D. G., Abraham, J. E., Earl, H. M., Hiller, Louise, Dunn, Janet A., Bowden, S., Berg, C., Campa, D., Diver, W. R., Gapstur, S. M., Gaudet, M. M., Hankinson, S. E., Hoover, R. N., Husing, A., Kaaks, R., Machiela, M. J., Willett, W., Barrdahl, M., Canzian, F., Chin, S.-F., Caldas, C., Hunter, D. J., Lindstrom, S., Garcia-Closas, M., Hall, P., Easton, D. F., Eccles, D. M., Rahman, N., Nevanlinna, H., Pharoah, P. D. P.

    Identification of Novel Genetic Markers of Breast Cancer Survival. JNCI Journal of the National Cancer Institute, 107 (5)
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A et al (Select to open full list), 2015.

    All authors for Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial

    Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A, Hayward, Larry

    Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial. The Lancet Oncology, 16 (6), pp. 656-666
  • Ali, H. R., Glont, S.- E., Blows, F. M., Provenzano, E., Dawson, S.- J., Liu, B., Hiller, Louise, Dunn, Janet A., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D. P., Caldas, C., 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26 (7)
  • Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael et al (Select to open full list), 2015.

    All authors for Common germline polymorphisms associated with breast cancer-specific survival

    Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael, Lambrechts, Dieter, Weltens, Caroline, Leunen, Karin, van Ongeval, Chantal, Nordestgaard, Børge G, Nielsen, Sune F, Flyger, Henrik, Rudolph, Anja, Seibold, Petra, Flesch-Janys, Dieter, Blomqvist, Carl, Aittomäki, Kristiina, Fagerholm, Rainer, Muranen, Taru A, Olsen, Janet E, Hallberg, Emily, Vachon, Celine, Knight, Julia A, Glendon, Gord, Mulligan, Anna Marie, Broeks, Annegien, Cornelissen, Sten, Haiman, Christopher A, Henderson, Brian E, Schumacher, Frederick, Le Marchand, Loic, Hopper, John L, Tsimiklis, Helen, Apicella, Carmel, Southey, Melissa C, Cross, Simon S, Reed, Malcolm WR, Giles, Graham G, Milne, Roger L, McLean, Catriona, Winqvist, Robert, Pylkäs, Katri, Jukkola-Vuorinen, Arja, Grip, Mervi, Hooning, Maartje J, Hollestelle, Antoinette, Martens, John WM, van den Ouweland, Ans MW, Marme, Federick, Schneeweiss, Andreas, Yang, Rongxi, Burwinkel, Barbara, Figueroa, Jonine, Chanock, Stephen J, Lissowska, Jolanta, Sawyer, Elinor J, Tomlinson, Ian, Kerin, Michael J, Miller, Nicola, Brenner, Hermann, Butterbach, Katja, Holleczek, Bernd, Kataja, Vesa, Kosma, Veli-Matti, Hartikainen, Jaana M, Li, Jingmei, Brand, Judith S, Humphreys, Keith, Devilee, Peter, Tollenaar, Robert AEM, Seynaeve, Caroline, Radice, Paolo, Peterlongo, Paolo, Manoukian, Siranoush, Ficarazzi, Filomena, Beckmann, Matthias W, Hein, Alexander, Ekici, Arif B, Balleine, Rosemary, Phillips, Kelly-Anne, Benitez, Javier, Zamora, M Pilar, Perez, Jose Ignacio Arias, Menéndez, Primitiva, Jakubowska, Anna, Lubinski, Jan, Gronwald, Jacek, Durda, Katarzyna, Hamann, Ute, Kabisch, Maria, Ulmer, Hans Ulrich, Rüdiger, Thomas, Margolin, Sara, Kristensen, Vessela, Nord, Siljie, Evans, D Gareth, Abraham, Jean, Earl, Helena, Poole, Christopher J, Hiller, Louise, Dunn, Janet A., Bowden, Sarah, Yang, Rose, Campa, Daniele, Diver, W Ryan, Gapstur, Susan M, Gaudet, Mia M, Hankinson, Susan, Hoover, Robert N, Hüsing, Anika, Kaaks, Rudolf, Machiela, Mitchell J, Willett, Walter, Barrdahl, Myrto, Canzian, Federico, Chin, Suet-Feung, Caldas, Carlos, Hunter, David J, Lindstrom, Sara, Garcia-Closas, Montserrat, Couch, Fergus J, Chenevix-Trench, Georgia, Mannermaa, Arto, Andrulis, Irene L, Hall, Per, Chang-Claude, Jenny, Easton, Douglas F, Bojesen, Stig E, Cox, Angela, Fasching, Peter A, Pharoah, Paul DP, Schmidt, Marjanka K

    Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17 (1)
  • Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014.

    All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

    Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon, Dunn, Janet A., Provenzano, Elena, Caldas, Carlos

    Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, Volulme 15 (2), pp. 201-212
  • Abraham, J. E., Guo, Q., Dorling, L., Tyrer, J., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, Louise, Burns, R., Jones, L., Bowden, S. J., Dunn, Janet A., Poole, C. J., Caldas, C., Pharoah, P. P. D., Earl, Helena M., 2014. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clinical Cancer Research, 20 (9), pp. 2466-2475
  • Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014.

    All authors for Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial

    Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon, Dunn, Janet A., Provenzano, Elena, Caldas, Carlos

    Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, 15 (2), pp. 201-212
  • Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014.

    All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

    Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P., Caldas, C.

    Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
  • Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014.

    All authors for Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

    Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P., Caldas, C.

    Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
  • Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
  • Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
  • Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A., Earl, Helena M., 2013. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, 108 (4), pp. 866-872
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012.

    All authors for Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

    Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A., McAdam, K., Foster, Liz, Leonard, R. C. F., Twelves, Chris, Cameron, D., Bartlett, J. M. S., Pharoah, P., Provenzano, E., Caldas, C., Poole, Christopher J.

    Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
  • Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
  • Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
  • Gounaris, I., Provenzano, E., Vallier, A. L., Hiller, Louise, Iddawela, M., Hilborne, S., Taylor, K. (Kathryn), Britton, Peter, Earl, Helena M., Sinnatamby, R., 2011. Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 127 (2), pp. 459-469
  • Hannigan, Adèle, Smith, Paul J., Kalna, Gabriela, Lo Nigro, Cristiana, Orange, Clare, O'Brien, Darren I., Shah, Reshma, Syed, Nelofer, Spender, Lindsay C., Herrera, Blanca, Thurlow, Johanna K., Lattanzio, Laura, Monteverde, Martino, Maurer, Meghan E., Buffa, Francesca M., Mann, Jelena, Chu, David C. K., West, Catharine M. L., Patridge, Max, Oien, Karin A. et al (Select to open full list), 2010.

    All authors for Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter

    Hannigan, Adèle, Smith, Paul J., Kalna, Gabriela, Lo Nigro, Cristiana, Orange, Clare, O'Brien, Darren I., Shah, Reshma, Syed, Nelofer, Spender, Lindsay C., Herrera, Blanca, Thurlow, Johanna K., Lattanzio, Laura, Monteverde, Martino, Maurer, Meghan E., Buffa, Francesca M., Mann, Jelena, Chu, David C. K., West, Catharine M. L., Patridge, Max, Oien, Karin A., Cooper, Jonathan A., Frame, Margaret C., Harris, Adrian L., Hiller, Louise, Nicholson, Linda J., Gasco, Milena, Crook, Tim, Inman, Gareth J.

    Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, Vol.120 (No.8), pp. 2842-2857
  • Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
  • Nicholson, Linda J., Smith, Paul R., Hiller, Louise, Szlosarek, Peter W., Kimberley, Christopher, Sehouli, Jalid, Koensgen, Dominique, Mustea, Alexander, Schmid, Peter, Crook, Tim, 2009. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. International Journal of Cancer, Vol.125 (No.6), pp. 1454-1463
  • Pepper, Chris, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul, Hiller, Louise, Hills, R., Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana, Fegan, Chris, 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, Vol.112 (No.9), pp. 3807-3817
  • Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
  • Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
  • Smith, Paul, Nicholson, Linda J., Syed, Nelofer, Payne, Annette, Hiller, Louise, Garrone, Ornella, Occelli, Marcella, Gasco, Milena, Crook, Tim, 2007. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clinical Cancer Research, Vol.13 (No.14), pp. 4061-4068
  • Ainsworth, R., Dziedzic, K., Hiller, Louise, Daniels, J., Bruton, A., Broadfield, J., 2007. A prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain. Rheumatology, Vol.46 (No.5), pp. 815-820
  • Donnelly, P., Hiller, Louise, Bathers, S., Bowden, S., Coleman, R., 2007. Questioning specialists' attitudes to breast cancer follow-up in primary care. Annals of Oncology, 18 (9), pp. 1467-1476
  • Tennant, Ruth, Hiller, Louise, Fishwick, Ruth, Platt, Stephen, Joseph, Stephen, Weich, Scott, Parkinson, Jane, Secker, Jenny, Stewart-Brown, Sarah L., 2007. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS) : development and UK validation. Health and Quality of Life Outcomes, Vol.5 (No.63)
  • Piper, M. K., Raza, K., Nuttall, S. L., Stevens, R., Toescu, V., Heaton, S., Gardner-Medwin, J., Hiller, Louise, Martin, U., Townend, J., Bacon, P. A., Gordon, Caroline, 2007. Impaired endothelial function in systemic lupus erythematosus. Lupus, Vol.16 (No.2), pp. 84-88
  • Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2007. Criterion validity of the BBUSQ-22: a questionnaire assessing bowel and urinary tract symptoms in women. International Urogynecology Journal, Vol.18 (No.10), pp. 1133-1137
  • Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
  • Pemberton, N. C., Paneesha, S., Hiller, Louise, Starczynski, J., Hooper, L., Pepper, C., Pratt, G., Fegan, C., 2006. The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leukemia & Lymphoma, 47 (7), pp. 1239-1244
  • Sullivan, Alexandra, Syed, Nelofer, Gasco, Milena, Bergamaschi, Daniele, Trigiante, Giuseppe, Attard, Marlene, Hiller, Louise, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2004. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene, 23 (19), pp. 3328-3337
  • Hussain, S. A., Palmer, D. H., Ganesan, R., Hiller, Louise, Gregory, J., Murray, P. G., Pastorek, J., Young, L., James, N. D., 2004. Carbonic anhydrase IX, a marker of hypoxia : correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncology Reports, 11 (5), pp. 1005-1010
  • Hussain, S. A., Ganesan, R., Hiller, Louise, Murray, P. G., El-Magraby, M. M., Young, L., James, N. D., 2003. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. British Journal of Cancer, 88 (4), pp. 586-592
  • Hussain, S. A., Ganesan, R., Hiller, Louise, Cooke, P. W., Murray, P., Young, L. S., James, N. D., 2003. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncology Reports, 10 (3), pp. 571-576
  • Hiller, Louise, Bradshaw, H. D., Radley, S. C., Radley, S., 2003. A scoring system for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 424-430
  • Wilson, D., Hiller, Louise, Gray, L., Grainger, M., Stirling, A., James, N., 2003. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clinical Oncology, 15 (7), pp. 400-407
  • Bergamaschi, Daniele, Gasco, Milena, Hiller, Louise, Sullivan, Alexandra, Syed, Nelofer, Trigiante, Giuseppe, Yulug, Isik, Merlano, Marco, Numico, Gianmauro, Comino, Alberto, Attard, Marlene, Reelfs, Olivier, Gusterson, Barry, Bell, Alexandra K., Heath, Victoria, Tavassoli, Mahvash, Farrell, Paul J, Smith, Paul, Lu, Xin, Crook, Tim, 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3 (4), pp. 387-402
  • Batta, Kapila, Goodyear, Helen M., Moss, Celia, Williams, Hywel C., Hiller, Louise, Waters, Ruth, 2002. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas : results of a 1-year analysis. The Lancet, 360 (9332), pp. 521-527
  • Gasco, M., Bell, A. K., Heath, V., Sullivan, A., Smith, P., Hiller, Louise, Yulug, I., Numico, G., Merlano, M., Farrell, P. J., Tavassoli, M., Gusterson, B., Crook, T., 2002. Epigenetic inactivation of 14-3-3 s in oral carcinoma : association with p16INK4a silencing and human papillomavirus negativity. Cancer Research, 62 (7), pp. 2072-2076
  • Hiller, Louise, Radley, S., Mann, C. H., Radley, S. C., Begum, G., Pretlove, S .J., Salaman, J. H., 2002. Development and validation of a questionnaire for the assessment of bowel and lower urinary tract symptoms in women. BJOG: An International Journal of Obstetrics and Gynaecology, 109 (4), pp. 413-423
  • Eggar, Richard, Spencer, Amanda, Anderson, David, Hiller, Louise, 2002. Views of elderly patients on cardiopulmonary resuscitation before and after treatment for depression. International Journal of Geriatric Psychiatry, 17 (2), pp. 170-174
  • Demain, Sara, Smith, Jan Fereday, Hiller, Louise, Dziedzic, Krysia, 2001. Comparison of group and individual physiotherapy for female urinary incontinence in primary care. Physiotherapy, 87 (5), pp. 235-242
  • Brooks, L. A., Tidy, J. A., Gusterson, B., Hiller, Louise, O'Nions, J., Gasco, M., Marin, M. C., Farrell, P. J., Kaelin, Jr., Crook, T., 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research, 60 (24), pp. 6875-6877
  • Darnton, S. J., Zgainski, B., Grenier, I., Allister, K., Hiller, Louise, McManus, K. G., Steyn, R. S., 1999. The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. Diseases of the Esophagus, 12 (4), pp. 283-288
  • Nicholl, D. J., Bennett, P., Hiller, Louise, Bonifati, V., Vanacore, N., Fabbrini, G., Marconi, R., Colosimo, C., Lamberti, P., Stocchi, F., Bonuccelli, U., Vieregge, P., Ramsden, D. B., Meco, G., Williams, A. C., 1999. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology, 53 (7), pp. 1415-1421
  • Etherington, I. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Hiller, Louise, Jordan, J. A., 1997. Observer variability among colposcopists from the West Midlands region. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (12), pp. 1380-1384
Title Funder Award start Award end
Sugammadex for preventIoN oF pOst-operative pulmoNary complIcAtions (SINFONIA) National Institute for Health Research (NIHR DoH) 01 Jun 2022 01 Nov 2026
NIHR PGfAR via Newcastle: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) National Institute for Health Research (DoH) 18 May 2020 17 May 2026
COBIx: Multi-site validation of automated AI tool for screening of large bowel endoscopic biopsy slides National Institute for Health Research (NIHR DoH) 01 Apr 2023 31 Mar 2026
NIHR Programme Grant:Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) Year 6 costs National Institute for Health Research (DoH) 03 Feb 2020 02 Feb 2026
NIHR HTA Stage 2: Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery ? a randomised controlled triaL (VITAL) National Institute for Health Research (NIHR DoH) 01 Nov 2020 30 Apr 2025
NIHR HTA Costed Extenison: Digital Pathology_Linked to Main award on IDEATE 58038 National Institute for Health Research (NIHR DoH) 01 Nov 2021 30 Apr 2023
ALIFE 2 extension 2 - link to 61060 Amsterdam Universitair Medische Centra 01 Mar 2020 14 Aug 2022
ALIFE 2 extension 2 - link to 61060 National Institute for Health Research (NIHR DoH) 01 Mar 2020 14 Aug 2022
ALIFE 2 extension 2 - link to 61060 National Institute for Health Research (DoH) 01 Mar 2020 28 Feb 2022
NIHR HTA: Whole slide imaging in pathology National Institute for Health Research (DoH) 01 Nov 2018 31 Oct 2021
ALIFE2-EXTENSION National Institute for Health Research (DoH) 01 May 2018 29 Feb 2020
Persephone extension and supplement National Institute for Health Research (DoH) 01 Jul 2016 30 Jun 2019
ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension Cambridge University Hospitals NHS Foundation Trust 01 Jul 2011 31 Dec 2018
Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer Artemis Year 9 Funding - staff - Late Phase Study Cancer Research UK 01 May 2017 30 Apr 2018
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Years 7,8 & 9 Support Funding Cancer Research UK 01 May 2015 30 Apr 2018
Second Recosting for extension of the Persephone HTA Trial National Institute for Health Research (DoH) 01 Jul 2013 30 Jun 2016
HTA FULL proposal: OPTIMA (Pilot Study) National Institute for Health Research (DoH) 01 Sep 2012 31 Aug 2013
3 month extention of the Persephone HTA Trial National Institute for Health Research (DoH) 01 Apr 2013 30 Jun 2013
Molecular profiling of post menopausal women with breast cancer on neoadjuvant exemestane or tamoxifen (MONET) University of Cambridge 01 Apr 2007 31 Mar 2009
Warwick Edinburgh Mental Wellbeing Scale: Proposal for Validation of the Scale on Data Collected in the HEBS Population Survey in September 2006 NHS Health Scotland 01 Jan 2007 30 May 2007